TRENBOLONE ACETATE - søkeresultat

xerdoxo 20 mg apvalkotās tabletes

krka, d.d., novo mesto, slovenia - rivaroksabans - apvalkotā tablete - 20 mg

Den europeiske union - latvisk - EMA (European Medicines Agency)

zercepac

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastiski līdzekļi - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. pirms ķīmijterapijas ir jāietver vismaz anthracycline un taxane, ja vien pacientiem ir derīgi šiem apstrādes veidiem. hormonu receptoru pozitīvu pacientiem jābūt arī neizdevās hormonu terapiju, ja vien pacientiem ir derīgi šiem apstrādes veidiem. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. kopā ar docetaxel par attieksmi pret pacientiem, kuri nav saņēmuši ķīmijterapiju to metastātiska slimība. kombinācijā ar aromatāzes inhibitoru, lai ārstētu menopauzes pacientiem ar hormonu receptoru pozitīvu mbc, kas agrāk nav ārstēti ar trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). pēc operācijas, ķīmijterapija (neoadjuvant vai palīgvielas) un staru terapijas laikā (ja piemērojams). šādas palīgvielas ķīmijterapija ar doksorubicīna un ciklofosfamīdu, kopā ar paclitaxel vai docetaxel. kopā ar palīgvielu ķīmijterapiju, kas sastāv no docetaxel un carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. precīza un apstiprinātas pārbaudes metodes vajadzētu izmantot,.

Latvia - latvisk - Zāļu valsts aģentūra

xanirva 10 mg cietās kapsulas

zentiva, k.s., czech republic - rivaroksabans - kapsula, cietā - 10 mg

Latvia - latvisk - Zāļu valsts aģentūra

xanirva 15 mg cietās kapsulas

zentiva, k.s., czech republic - rivaroksabans - kapsula, cietā - 15 mg

Latvia - latvisk - Zāļu valsts aģentūra

xanirva 20 mg cietās kapsulas

zentiva, k.s., czech republic - rivaroksabans - kapsula, cietā - 20 mg

Latvia - latvisk - Zāļu valsts aģentūra

rivaroxaban g.l. pharma 10 mg apvalkotās tabletes

g.l. pharma gmbh, austria - rivaroksabans - apvalkotā tablete - 10 mg